Welcome to our dedicated page for Cardiff Oncology news (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology stock.
Cardiff Oncology Inc (CRDF) is a clinical-stage biotech company advancing novel therapies targeting cancers with high unmet need through its focus on PLK1 inhibition. This page provides investors and researchers with timely updates on clinical developments, strategic initiatives, and scientific breakthroughs driving the company's precision oncology pipeline.
Access the latest CRDF news including trial updates for RAS-mutated mCRC and other challenging cancers, partnership announcements, and regulatory milestones. Our curated collection features press releases on onvansertib developments, peer-reviewed data highlights, and management commentary to inform your analysis of this innovative oncology player.
Key content categories include Phase 2 trial progress updates, scientific conference presentations, and operational developments shaping Cardiff's therapeutic pipeline. Bookmark this page for streamlined tracking of CRDF's efforts to transform cancer treatment through mechanism-driven approaches.
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotechnology firm specializing in PLK1 inhibition to develop cancer therapies, will present at the Jefferies Healthcare Conference in New York on June 5-6, 2024. CEO Mark Erlander will present on June 5, 2024, from 8:30 to 8:55 AM ET in Track 8. The company will also hold 1x1 meetings with investors. Interested parties can access live webcasts and replays of the presentations via Cardiff Oncology's website.
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotechnology company, will present at two investor conferences in May 2024. The first, H.C. Wainwright 2nd Annual BioConnect Investor Conference, will be held at the Nasdaq Headquarters in New York City on May 20, 2024, at 2:30 PM ET. The second, Cowen 5th Annual Oncology Innovation Summit, will be a virtual event on May 29, 2024, at 1:30 PM ET. CEO Mark Erlander will represent Cardiff Oncology in fireside chats at both events. Interested parties can access live webcasts via Cardiff Oncology's website, with replays available post-event.
Cardiff Oncology, Inc. (Nasdaq: CRDF) reported Q1 2024 results and provided a business update, highlighting strong efficacy in RAS-mutated mCRC and onvansertib's potential across various cancers. The company has $67M in cash, projecting runway into Q3 2025. Key milestones include upcoming data readouts, trials, and preclinical data presentations. Financially, total operating expenses decreased, with funds expected to last into Q3 2025.
FAQ
What is the current stock price of Cardiff Oncology (CRDF)?
What is the market cap of Cardiff Oncology (CRDF)?
